Literature DB >> 24497212

Hypogonadism in aged hospitalized male patients: prevalence and clinical outcome.

P Iglesias1, F Prado, M C Macías, M T Guerrero, A Muñoz, E Ridruejo, P Tajada, C García-Arévalo, J J Díez.   

Abstract

OBJECTIVE: Male hypogonadism is common in the elderly and has been associated with increased risk of mortality. Our objective has been to assess the prevalence of primary and central hypogonadism in elderly male patients admitted to the hospital because of acute illness. We also evaluated the relationships between gonadal dysfunction and in-hospital mortality. PATIENTS AND METHODS: 150 patients, aged ≥65 years, admitted during 2010 and 2011 in our geriatric unit, were studied. Serum concentrations total, bioavailable and free testosterone, as well as of follicle-stimulating hormone and luteinizing hormone were quantified in every patient. Hypogonadism was defined by the presence of serum testosterone levels lower than 200 ng/dl.
RESULTS: Hypogonadism was found in 80 patients (53.3 %). Serum gonadotropin concentrations were elevated in 43.7 % of these patients, whereas 41.3 % of hypogonadic patients showed normal and 15 % low gonadotropin concentrations. Respiratory tract infection and congestive heart failure were the main causes of hospitalization in hypogonadal men, whereas acute cerebrovascular disease was the main reason for admission in eugonadal patients. Of the 13 patients who died during hospitalization, 12 were hypogonadic. Patients who died showed significantly lower serum levels of total, free and bioavailable testosterone than those found in patients who survived.
CONCLUSION: Our results show that about half of patients admitted for acute illness have hypogonadism, mainly of non-hypergonadotropic type. Gonadal hypofunction is significantly related with in-hospital mortality. A low value of serum testosterone may be a predictor for mortality in elderly male patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24497212     DOI: 10.1007/s40618-013-0009-x

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  31 in total

Review 1.  Age-related changes in testosterone and the role of replacement therapy in older men.

Authors:  Carolyn A Allan; Robert I McLachlan
Journal:  Clin Endocrinol (Oxf)       Date:  2004-06       Impact factor: 3.478

2.  Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study.

Authors:  Kay-Tee Khaw; Mitch Dowsett; Elizabeth Folkerd; Sheila Bingham; Nicholas Wareham; Robert Luben; Ailsa Welch; Nicholas Day
Journal:  Circulation       Date:  2007-11-26       Impact factor: 29.690

3.  Serum testosterone but not leptin predicts mortality in elderly men.

Authors:  Aapo Lehtonen; Risto Huupponen; Jaakko Tuomilehto; Sirkku Lavonius; Seija Arve; Hannu Isoaho; Ilpo Huhtaniemi; Reijo Tilvis
Journal:  Age Ageing       Date:  2008-03-12       Impact factor: 10.668

4.  Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.

Authors:  S M Harman; E J Metter; J D Tobin; J Pearson; M R Blackman
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

5.  Diagnosis of hypogonadism in the aging male.

Authors:  A Vermeulen; J M Kaufman
Journal:  Aging Male       Date:  2002-09       Impact factor: 5.892

6.  The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men.

Authors:  Thomas G Travison; Andre B Araujo; Varant Kupelian; Amy B O'Donnell; John B McKinlay
Journal:  J Clin Endocrinol Metab       Date:  2006-12-05       Impact factor: 5.958

Review 7.  Androgens and cardiovascular disease.

Authors:  Bu B Yeap
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-06       Impact factor: 3.243

8.  Association of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and all-cause mortality in elderly men from the Framingham Heart Study.

Authors:  Robin Haring; Zhaoyang Teng; Vanessa Xanthakis; Andrea Coviello; Lisa Sullivan; Shalender Bhasin; Joanne M Murabito; Henri Wallaschofski; Ramachandran S Vasan
Journal:  Clin Endocrinol (Oxf)       Date:  2013-04       Impact factor: 3.478

9.  Lower testosterone levels predict incident stroke and transient ischemic attack in older men.

Authors:  Bu B Yeap; Zoë Hyde; Osvaldo P Almeida; Paul E Norman; S A Paul Chubb; Konrad Jamrozik; Leon Flicker; Graeme J Hankey
Journal:  J Clin Endocrinol Metab       Date:  2009-04-07       Impact factor: 5.958

10.  Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study.

Authors:  Frederick C W Wu; Abdelouahid Tajar; Stephen R Pye; Alan J Silman; Joseph D Finn; Terence W O'Neill; Gyorgy Bartfai; Felipe Casanueva; Gianni Forti; Aleksander Giwercman; Ilpo T Huhtaniemi; Krzysztof Kula; Margus Punab; Steven Boonen; Dirk Vanderschueren
Journal:  J Clin Endocrinol Metab       Date:  2008-02-12       Impact factor: 5.958

View more
  14 in total

Review 1.  Testosterone supplementation and body composition: results from a meta-analysis of observational studies.

Authors:  G Corona; V A Giagulli; E Maseroli; L Vignozzi; A Aversa; M Zitzmann; F Saad; E Mannucci; M Maggi
Journal:  J Endocrinol Invest       Date:  2016-05-30       Impact factor: 4.256

2.  How to define hypogonadism? Results from a population of men consulting for sexual dysfunction.

Authors:  G Rastrelli; G Corona; M Tarocchi; E Mannucci; M Maggi
Journal:  J Endocrinol Invest       Date:  2016-01-05       Impact factor: 4.256

3.  Serum testosterone levels and mortality in men with CKD stages 3-4.

Authors:  Kiranpreet K Khurana; Sankar D Navaneethan; Susana Arrigain; Jesse D Schold; Joseph V Nally; Daniel A Shoskes
Journal:  Am J Kidney Dis       Date:  2014-04-13       Impact factor: 8.860

4.  Natural course of hypogonadism diagnosed during hospitalization in aged male patients.

Authors:  P Iglesias; F Prado; A Muñoz; M T Guerrero; M C Macías; E Ridruejo; P Tajada; C García-Arévalo; J J Díez
Journal:  Endocrine       Date:  2014-09-10       Impact factor: 3.633

5.  The relationship of depression in asthma-chronic obstructive pulmonary disease overlap syndrome.

Authors:  Jun-Jun Yeh; Cheng-Li Lin; Wu-Huei Hsu; Chia-Hung Kao
Journal:  PLoS One       Date:  2017-12-12       Impact factor: 3.240

6.  Screening for low testosterone is needed for early identification and treatment of men at high risk of mortality from Covid-19.

Authors:  Simon Peter Rowland; Elizabeth O'Brien Bergin
Journal:  Crit Care       Date:  2020-06-19       Impact factor: 9.097

7.  Testosterone Deficiency Is a Risk Factor for Severe COVID-19.

Authors:  Lukas Lanser; Francesco Robert Burkert; Lis Thommes; Alexander Egger; Gregor Hoermann; Susanne Kaser; Germar Michael Pinggera; Markus Anliker; Andrea Griesmacher; Günter Weiss; Rosa Bellmann-Weiler
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-18       Impact factor: 5.555

8.  Associations Between Low Serum Testosterone and All-Cause Mortality and Infection-Related Hospitalization in Male Hemodialysis Patients: A Prospective Cohort Study.

Authors:  Akio Nakashima; Ichiro Ohkido; Keitaro Yokoyama; Aki Mafune; Mitsuyoshi Urashima; Takashi Yokoo
Journal:  Kidney Int Rep       Date:  2017-08-04

Review 9.  Worse progression of COVID-19 in men: Is testosterone a key factor?

Authors:  Vito A Giagulli; Edoardo Guastamacchia; Thea Magrone; Emilio Jirillo; Giuseppe Lisco; Giovanni De Pergola; Vincenzo Triggiani
Journal:  Andrology       Date:  2020-06-28       Impact factor: 4.456

10.  Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients.

Authors:  Giulia Rastrelli; Vincenza Di Stasi; Francesco Inglese; Massimiliano Beccaria; Martina Garuti; Domenica Di Costanzo; Fabio Spreafico; Graziana Francesca Greco; Giulia Cervi; Antonietta Pecoriello; Angela Magini; Tommaso Todisco; Sarah Cipriani; Elisa Maseroli; Giovanni Corona; Andrea Salonia; Andrea Lenzi; Mario Maggi; Giuseppe De Donno; Linda Vignozzi
Journal:  Andrology       Date:  2020-06-03       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.